Navigation Links
Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
Date:12/10/2012

y is to define the maximum tolerated dose of quizartinib when given as maintenance therapy after treatment with an allogeneic HSCT.  Patient enrollment is ongoing.

About Quizartinib
Quizartinib (AC220) is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor being developed in collaboration between Ambit Biosciences Corporation and Astellas Pharma Inc. Quizartinib is currently under evaluation in a Phase 2b clinical trial as monotherapy treatment for adult patients with relapsed or refractory AML, and in two Phase 1 studies in a combination treatment regimen with chemotherapy, and as a maintenance therapy following transplant, respectively.

About Ambit Biosciences
Ambit Biosciences is a privately held biopharmaceutical company engaged in the development of a robust pipeline of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease and other indications. Ambit's lead compound, quizartinib (AC220), is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML and treatment-naive AML. Ambit is developing quizartinib in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to quizartinib, Ambit's clinical pipeline includes AC430, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program. For more information, visit www.ambitbio.com.

About Astellas Pharma Inc.
Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. Astellas
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
2. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
3. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
4. Personal Connections Drive Employee Participation For Changing Tomorrow Day at Astellas
5. Astellas to Close Urogenix, North Carolina-based Urology Research Facility
6. Astellas and Fujita Health University Discover Neuronal Maturation Deficits in Patients Suffering from Schizophrenia and Bipolar Disorder
7. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
8. Xstelos Holdings Announces Dividend
9. Medbox, Inc. Announced Increased Funding for Corporate Giving Program in 2013
10. Biogen Idec and Isis Pharmaceuticals Announce Collaboration For Antisense Programs To Treat Neurological Disorders
11. IRIDEX Corporation Announces Preliminary Results of its Tender Offer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014   Royal Philips (NYSE: ... has received 510(k) clearance from the U.S. Food ... application for Transcatheter Aortic-Valve Implantation (TAVI) treatments. Through ... with pre-procedural, high-precision positioning to treat aortic stenosis ... is available as part of Philips IntelliSpace ...
(Date:8/21/2014)... CYBX ) today announced results for the quarter ...   Operating results for the first quarter of ... and other achievements, include: , Worldwide net product sales ... international net sales of $13.2 million, an increase of 14.5% ... sales reached a new high of $58.8 million, an increase ...
(Date:8/21/2014)... 2014  SI-BONE, Inc. ( San Jose, California ... use of the iFuse Implant System, ® a ... the sacroiliac (SI) joint, announced that Priority Health ( ... Lumbar Fusion Medical Policy No. 91590-R4 providing positive coverage ... states that the fusion procedure, which employs the iFuse ...
Breaking Medicine Technology:Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3
(Date:8/21/2014)... DMG Productions announces the upcoming airing of Innovations ... August 25, 2014 at 7:00 a.m. EST and 7:00 ... episode, Innovations will go behind-the-scenes to demonstrate how Freenotes ... Audiences will be amazed by the park's that focus ... providing access to real musical instruments. , Audiences will ...
(Date:8/21/2014)... August 21, 2014 Being overweight or ... painful osteoarthritis. Although there is no cure, patients have ... making certain lifestyle changes, such as losing excess weight ... , Osteoarthritis is a joint disorder which causes discomfort ... and neck and can significantly reduce one’s quality of ...
(Date:8/21/2014)... Australian scientists say a commercially available compound ... used to successfully fight mesothelioma in lab mice. Surviving ... research. Click here to read it now. ... mesothelioma cells with the S. aureus mixture ... simultaneously stimulating a stronger anti-tumor response in healthy cells. ...
(Date:8/21/2014)... Louis, MO (PRWEB) August 21, 2014 ... wellness in all aspects of life, St. Louis’ Sound ... for the better and revolutionized its online presence. Reorganized ... Mind Café, the new website makes navigating for information ... blue and an easily accessible menu-bar in jet black, ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Bunion Bootie ... Pedorthics, a bi-monthly publication of the Pedorthic Footcare Association and ... , Bunion Bootie is a new ... for bunion sufferers and their pain. It is extremely comfortable ... any shoe to eliminate the friction and rubbing of shoes ...
Breaking Medicine News(10 mins):Health News:Announcing New Episode Airing of Innovations on Monday August 25, 2014 via Discovery Channel 2Health News:Diet Doc’s Medical Weight Loss Programs Announces Safe and Fast Weight Loss That Teach Patients How to Relieve Osteoarthritis Pain 2Health News:Diet Doc’s Medical Weight Loss Programs Announces Safe and Fast Weight Loss That Teach Patients How to Relieve Osteoarthritis Pain 3Health News:Study Finds Bacteria Compound Shrinks Mesothelioma Tumors, According to Surviving Mesothelioma 2Health News:Sound Mind Cafe Launches Revamped Website and Hires Hypnotist to Team 2Health News:Recently Featured in Current Pedorthics: Bunion Bootie, the Very Popular Bunion Treatment Splint 2Health News:Recently Featured in Current Pedorthics: Bunion Bootie, the Very Popular Bunion Treatment Splint 3
... China is implementing family planning policies is often held ... ,Well the element of coercion may be ... exploding beyond relentlessly.,The riots against punitive measures reported last ... being done over there.,Worse, the Chinese citizens are virtually ...
... stents in the treatment of coronary artery blockage is common ... patients receiving drug-coated stents for off-label indications, according to ... ,Stents are tiny mesh tubes used to prop open ... obstructed coronary artery. The newer drug-eluting stents are normal metal ...
... of tuberculosis in Britain, senior doctors here want all ... the disease. ,The doctors want the ... ,The Observer reported Sunday that two new outbreaks, in ... officials were failing to come to grips with the ...
... Researchers studying the genetics behind why C. difficile causes disease ... it because they are starving. That just might help them ... a very difficult disease to treat. ,"The genes ... periods of nutrient deprivation. This is consistent with the view ...
... person dies of it every 30 seconds, it rivals HIV ... vast majority of its victims are under five years old. ... Ross was awarded the Nobel Prize for finally proving that ... Nottingham believe they have made a significant breakthrough in the ...
... Commissioner for Human Rights: 'Universal access to health care is not ... cannot implement that human right without effective health systems. We ... this simple message stick.' ,The International Day ... year. ,The origins of this world health day ...
Cached Medicine News:Health News:Chinese Take Fertility Drugs to Beat One Child Policy 2Health News:Chinese Take Fertility Drugs to Beat One Child Policy 3Health News:Off-label and Untested Use of Drug-coated Stents Appears Widespread 2Health News:Understanding Why C. Difficile Causes Disease -- It's Hungry 2Health News:Vaccine Hope for Malaria 2Health News:International Day Of Action For Women's Health - 2007 2Health News:International Day Of Action For Women's Health - 2007 3Health News:International Day Of Action For Women's Health - 2007 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: